Saturday, June 25, 2016

Titan Medical director resigns following AGM vote

Titan Medical director resigns following AGM vote

June 23, 2016 by · Leave a Comment 

Tweet At the annual meeting of Titan Medical (TSX:TMD), shareholders voted against reelecting John Hargrove, CEO and chairman, as a director. Mr. Hargrove received 42% of votes cast in favor of reelection and 58% against. Following the meeting, Mr. Hargrove tendered his resignation as a director of Titan Medical in accordance with the company’s majority […]

Anavex gets orphan drug status for infantile spasms

Anavex gets orphan drug status for infantile spasms

June 22, 2016 by · Leave a Comment 

Tweet Anavex Life Sciences (NASDAQ:AVXL) has received FDA orphan drug designation for ANAVEX 2-73 for the treatment of infantile spasms. ANAVEX 2-73 already has orphan drug designation for the treatment of Rett syndrome. An infantile spasm is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. […]

Titan Pharma gains more media attention

Titan Pharma gains more media attention

June 20, 2016 by · Leave a Comment 

Tweet NBC News has become the latest media outlet to feature Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant for people addicted to heroin and prescription painkillers. As an implantable version of oral buprenorphine, which is a drug designed to ease withdrawal symptoms, FDA-approved Probuphine is a new hope for those caught in the fight of their lives […]

First patients treated with Titan Pharma’s Probuphine

First patients treated with Titan Pharma’s Probuphine

June 20, 2016 by · Leave a Comment 

Tweet The first 10 patients received treatment last week with Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine, following FDA approval on May 26. Probuphine was developed using Titan’s long-term, continuous drug delivery platform, ProNeura, for the maintenance treatment of opioid dependence. To date, more than 1,000 health care providers in 44 states have been trained […]

Braeburn presents Probuphine data at CPDD meeting

Braeburn presents Probuphine data at CPDD meeting

June 16, 2016 by · Leave a Comment 

Tweet Closely-held Braeburn Pharmaceuticals has presented data from the poster of the Phase 3 study of Probuphine, a six-month subdermal buprenorphine implant for the long-term maintenance treatment of opioid dependence, at the annual scientific meeting of The College on Problems of Drug Dependence (CPDD). The FDA recently approved Probuphine, which was developed by its partner, […]

Titan Pharma sensitivity analyses confirm efficacy of Probuphine

Titan Pharma sensitivity analyses confirm efficacy of Probuphine

June 15, 2016 by · Leave a Comment 

Tweet Titan Pharmaceuticals (NASDAQ: TTNP) is presenting data today from four post hoc sensitivity analyses of the final Phase 3 trial of Probuphine at a poster session during The College on Problems of Drug Dependence 78th Annual Meeting in Palm Springs. Probuphine is a six-month subdermal buprenorphine implant for the long-term maintenance treatment of opioid […]

S1 Biopharma to start Phase 2b study in female HSDD by yearend

S1 Biopharma to start Phase 2b study in female HSDD by yearend

June 14, 2016 by · Leave a Comment 

Tweet Closely-held S1 Biopharma expects to initiate a Phase 2b study at the end of the year with its lead product candidate for female hypoactive sexual desire disorder (HSDD), Lorexys, and a Phase 2a program with a second therapy, Orexa, for male HSDD. “HSDD is characterized by a lack or absence of sexual fantasies and […]

Titan Pharma receives milestone on Probuphine approval

Titan Pharma receives milestone on Probuphine approval

June 13, 2016 by · Leave a Comment 

Tweet Titan Pharmaceuticals (NASDAQ:TTNP) has received a $15-million milestone payment from development and commercialization partner, Braeburn Pharmaceuticals, following FDA approval of Probuphine, the first six-month maintenance treatment of opioid dependence. Under terms of the licensing agreement, closely-held Braeburn will pay Titan tiered royalties on net sales in the U.S. and Canada at rates ranging from […]

Canaccord ups GenMark price target to $10.50

Canaccord ups GenMark price target to $10.50

June 9, 2016 by · Leave a Comment 

Tweet Canaccord Genuity has hiked its price target for GenMark Diagnostics (NASDAQ:GNMK) to $10.50 from $8. The stock closed at $9.27 on Wednesday. After the close yesterday, GNMK announced a major milestone, achieving CE Mark for both its ePlex instrument and ePlex Respiratory Pathogen Panel, which was three weeks ahead of its recent timeline by […]

Roth reinitiates coverage of Cempra at buy

Roth reinitiates coverage of Cempra at buy

June 7, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has reinitiated coverage of Cempra (NASDAQ:CEMP) with a “buy” rating and $37 price target. The stock closed at $19.48 on Monday. “With impressive pivotal studies on solithromycin (Solitaire-IV and Solitaire-Oral), we encourage investors to accumulate a position in Cempra as the company leverages its clinical data in treating community acquired bacterial […]

Next Page »

Email Newsletters with Constant Contact
Google+